within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CB02_Octreotide;

model Octreotide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.611111111111111e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0136,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0104,
    k12 = 7.5e-08,
    k21 = 7.5e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Octreotide</td></tr><tr><td>ATC code:</td><td>H01CB02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.58</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Octreotide is a synthetic octapeptide and somatostatin analogue that inhibits the release of several hormones such as growth hormone and insulin. It is used clinically for the management of acromegaly, treatment of severe diarrhea and flushing associated with carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), and other neuroendocrine tumors. Octreotide is currently approved and in use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after subcutaneous administration.</p><h4>References</h4><ol><li><p>Glatard, A, et al., &amp; Tiberg, F (2025). Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly. <i>Clinical pharmacokinetics</i> None –. DOI:<a href=\"https://doi.org/10.1007/s40262-025-01522-3\">10.1007/s40262-025-01522-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40418492/\">https://pubmed.ncbi.nlm.nih.gov/40418492</a></p></li><li><p>Comets, E, et al., &amp; Vonderscher, J (2003). Population pharmacodynamic analysis of octreotide in acromegalic patients. <i>Clinical pharmacology and therapeutics</i> 73(1) 95–106. DOI:<a href=\"https://doi.org/10.1067/mcp.2003.6\">10.1067/mcp.2003.6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12545148/\">https://pubmed.ncbi.nlm.nih.gov/12545148</a></p></li><li><p>Dogliotti, L, et al., &amp; Fabiani, L (2001). The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 12 Suppl 2 S105–S109. DOI:<a href=\"https://doi.org/10.1093/annonc/12.suppl_2.s105\">10.1093/annonc/12.suppl_2.s105</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11762334/\">https://pubmed.ncbi.nlm.nih.gov/11762334</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H01CB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Octreotide;
